The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hyperimmune Globulin Injection Market Research Report 2024
Synopsis
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Global Hyperimmune Globulin Injection market is projected to reach US$ 2839.8 million in 2029, increasing from US$ 1867 million in 2022, with the CAGR of 6.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hyperimmune Globulin Injection market research.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Hyperimmune Globulin Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Segment by Type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other
Segment by Application
Government Institution
Private Sector
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Hyperimmune Globulin Injection report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Global Hyperimmune Globulin Injection market is projected to reach US$ 2839.8 million in 2029, increasing from US$ 1867 million in 2022, with the CAGR of 6.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hyperimmune Globulin Injection market research.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Hyperimmune Globulin Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Segment by Type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other
Segment by Application
Government Institution
Private Sector
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Hyperimmune Globulin Injection report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Hyperimmune Globulin Injection Market Overview
1.1 Product Overview and Scope of Hyperimmune Globulin Injection
1.2 Hyperimmune Globulin Injection Segment by Type
1.2.1 Global Hyperimmune Globulin Injection Market Value Comparison by Type (2023-2029)
1.2.2 Hepatitis B Immunoglobulins
1.2.3 Rabies Immunoglobulins
1.2.4 Tetanus Immunoglobulins
1.2.5 Rho(D) Immunoglobulins
1.2.6 Other
1.3 Hyperimmune Globulin Injection Segment by Application
1.3.1 Global Hyperimmune Globulin Injection Market Value by Application: (2023-2029)
1.3.2 Government Institution
1.3.3 Private Sector
1.3.4 Others
1.4 Global Hyperimmune Globulin Injection Market Size Estimates and Forecasts
1.4.1 Global Hyperimmune Globulin Injection Revenue 2018-2029
1.4.2 Global Hyperimmune Globulin Injection Sales 2018-2029
1.4.3 Global Hyperimmune Globulin Injection Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Hyperimmune Globulin Injection Market Competition by Manufacturers
2.1 Global Hyperimmune Globulin Injection Sales Market Share by Manufacturers (2018-2023)
2.2 Global Hyperimmune Globulin Injection Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Hyperimmune Globulin Injection Average Price by Manufacturers (2018-2023)
2.4 Global Hyperimmune Globulin Injection Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Hyperimmune Globulin Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hyperimmune Globulin Injection, Product Type & Application
2.7 Hyperimmune Globulin Injection Market Competitive Situation and Trends
2.7.1 Hyperimmune Globulin Injection Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Hyperimmune Globulin Injection Players Market Share by Revenue
2.7.3 Global Hyperimmune Globulin Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hyperimmune Globulin Injection Retrospective Market Scenario by Region
3.1 Global Hyperimmune Globulin Injection Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Hyperimmune Globulin Injection Global Hyperimmune Globulin Injection Sales by Region: 2018-2029
3.2.1 Global Hyperimmune Globulin Injection Sales by Region: 2018-2023
3.2.2 Global Hyperimmune Globulin Injection Sales by Region: 2024-2029
3.3 Global Hyperimmune Globulin Injection Global Hyperimmune Globulin Injection Revenue by Region: 2018-2029
3.3.1 Global Hyperimmune Globulin Injection Revenue by Region: 2018-2023
3.3.2 Global Hyperimmune Globulin Injection Revenue by Region: 2024-2029
3.4 North America Hyperimmune Globulin Injection Market Facts & Figures by Country
3.4.1 North America Hyperimmune Globulin Injection Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Hyperimmune Globulin Injection Sales by Country (2018-2029)
3.4.3 North America Hyperimmune Globulin Injection Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Hyperimmune Globulin Injection Market Facts & Figures by Country
3.5.1 Europe Hyperimmune Globulin Injection Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Hyperimmune Globulin Injection Sales by Country (2018-2029)
3.5.3 Europe Hyperimmune Globulin Injection Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hyperimmune Globulin Injection Market Facts & Figures by Country
3.6.1 Asia Pacific Hyperimmune Globulin Injection Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Hyperimmune Globulin Injection Sales by Country (2018-2029)
3.6.3 Asia Pacific Hyperimmune Globulin Injection Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Hyperimmune Globulin Injection Market Facts & Figures by Country
3.7.1 Latin America Hyperimmune Globulin Injection Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Hyperimmune Globulin Injection Sales by Country (2018-2029)
3.7.3 Latin America Hyperimmune Globulin Injection Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hyperimmune Globulin Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Hyperimmune Globulin Injection Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Hyperimmune Globulin Injection Sales by Country (2018-2029)
3.8.3 Middle East and Africa Hyperimmune Globulin Injection Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Hyperimmune Globulin Injection Sales by Type (2018-2029)
4.1.1 Global Hyperimmune Globulin Injection Sales by Type (2018-2023)
4.1.2 Global Hyperimmune Globulin Injection Sales by Type (2024-2029)
4.1.3 Global Hyperimmune Globulin Injection Sales Market Share by Type (2018-2029)
4.2 Global Hyperimmune Globulin Injection Revenue by Type (2018-2029)
4.2.1 Global Hyperimmune Globulin Injection Revenue by Type (2018-2023)
4.2.2 Global Hyperimmune Globulin Injection Revenue by Type (2024-2029)
4.2.3 Global Hyperimmune Globulin Injection Revenue Market Share by Type (2018-2029)
4.3 Global Hyperimmune Globulin Injection Price by Type (2018-2029)
5 Segment by Application
5.1 Global Hyperimmune Globulin Injection Sales by Application (2018-2029)
5.1.1 Global Hyperimmune Globulin Injection Sales by Application (2018-2023)
5.1.2 Global Hyperimmune Globulin Injection Sales by Application (2024-2029)
5.1.3 Global Hyperimmune Globulin Injection Sales Market Share by Application (2018-2029)
5.2 Global Hyperimmune Globulin Injection Revenue by Application (2018-2029)
5.2.1 Global Hyperimmune Globulin Injection Revenue by Application (2018-2023)
5.2.2 Global Hyperimmune Globulin Injection Revenue by Application (2024-2029)
5.2.3 Global Hyperimmune Globulin Injection Revenue Market Share by Application (2018-2029)
5.3 Global Hyperimmune Globulin Injection Price by Application (2018-2029)
6 Key Companies Profiled
6.1 CSL Behring
6.1.1 CSL Behring Corporation Information
6.1.2 CSL Behring Description and Business Overview
6.1.3 CSL Behring Hyperimmune Globulin Injection Sales, Revenue and Gross Margin (2018-2023)
6.1.4 CSL Behring Hyperimmune Globulin Injection Product Portfolio
6.1.5 CSL Behring Recent Developments/Updates
6.2 Grifols
6.2.1 Grifols Corporation Information
6.2.2 Grifols Description and Business Overview
6.2.3 Grifols Hyperimmune Globulin Injection Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Grifols Hyperimmune Globulin Injection Product Portfolio
6.2.5 Grifols Recent Developments/Updates
6.3 Biotest
6.3.1 Biotest Corporation Information
6.3.2 Biotest Description and Business Overview
6.3.3 Biotest Hyperimmune Globulin Injection Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Biotest Hyperimmune Globulin Injection Product Portfolio
6.3.5 Biotest Recent Developments/Updates
6.4 Kedrion
6.4.1 Kedrion Corporation Information
6.4.2 Kedrion Description and Business Overview
6.4.3 Kedrion Hyperimmune Globulin Injection Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Kedrion Hyperimmune Globulin Injection Product Portfolio
6.4.5 Kedrion Recent Developments/Updates
6.5 CBPO
6.5.1 CBPO Corporation Information
6.5.2 CBPO Description and Business Overview
6.5.3 CBPO Hyperimmune Globulin Injection Sales, Revenue and Gross Margin (2018-2023)
6.5.4 CBPO Hyperimmune Globulin Injection Product Portfolio
6.5.5 CBPO Recent Developments/Updates
6.6 Emergent (Cangene)
6.6.1 Emergent (Cangene) Corporation Information
6.6.2 Emergent (Cangene) Description and Business Overview
6.6.3 Emergent (Cangene) Hyperimmune Globulin Injection Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Emergent (Cangene) Hyperimmune Globulin Injection Product Portfolio
6.6.5 Emergent (Cangene) Recent Developments/Updates
6.7 Kamada
6.6.1 Kamada Corporation Information
6.6.2 Kamada Description and Business Overview
6.6.3 Kamada Hyperimmune Globulin Injection Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Kamada Hyperimmune Globulin Injection Product Portfolio
6.7.5 Kamada Recent Developments/Updates
6.8 CNBG
6.8.1 CNBG Corporation Information
6.8.2 CNBG Description and Business Overview
6.8.3 CNBG Hyperimmune Globulin Injection Sales, Revenue and Gross Margin (2018-2023)
6.8.4 CNBG Hyperimmune Globulin Injection Product Portfolio
6.8.5 CNBG Recent Developments/Updates
6.9 Hualan Bio
6.9.1 Hualan Bio Corporation Information
6.9.2 Hualan Bio Description and Business Overview
6.9.3 Hualan Bio Hyperimmune Globulin Injection Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Hualan Bio Hyperimmune Globulin Injection Product Portfolio
6.9.5 Hualan Bio Recent Developments/Updates
6.10 Shanghai RAAS
6.10.1 Shanghai RAAS Corporation Information
6.10.2 Shanghai RAAS Description and Business Overview
6.10.3 Shanghai RAAS Hyperimmune Globulin Injection Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Shanghai RAAS Hyperimmune Globulin Injection Product Portfolio
6.10.5 Shanghai RAAS Recent Developments/Updates
6.11 Sichuan Yuanda Shuyang
6.11.1 Sichuan Yuanda Shuyang Corporation Information
6.11.2 Sichuan Yuanda Shuyang Hyperimmune Globulin Injection Description and Business Overview
6.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulin Injection Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Sichuan Yuanda Shuyang Hyperimmune Globulin Injection Product Portfolio
6.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
6.12 ADMA Biologics
6.12.1 ADMA Biologics Corporation Information
6.12.2 ADMA Biologics Hyperimmune Globulin Injection Description and Business Overview
6.12.3 ADMA Biologics Hyperimmune Globulin Injection Sales, Revenue and Gross Margin (2018-2023)
6.12.4 ADMA Biologics Hyperimmune Globulin Injection Product Portfolio
6.12.5 ADMA Biologics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hyperimmune Globulin Injection Industry Chain Analysis
7.2 Hyperimmune Globulin Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hyperimmune Globulin Injection Production Mode & Process
7.4 Hyperimmune Globulin Injection Sales and Marketing
7.4.1 Hyperimmune Globulin Injection Sales Channels
7.4.2 Hyperimmune Globulin Injection Distributors
7.5 Hyperimmune Globulin Injection Customers
8 Hyperimmune Globulin Injection Market Dynamics
8.1 Hyperimmune Globulin Injection Industry Trends
8.2 Hyperimmune Globulin Injection Market Drivers
8.3 Hyperimmune Globulin Injection Market Challenges
8.4 Hyperimmune Globulin Injection Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
